BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3436 related articles for article (PubMed ID: 26850970)

  • 21. PET Imaging for Prostate Cancer.
    Savir-Baruch B; Werner RA; Rowe SP; Schuster DM
    Radiol Clin North Am; 2021 Sep; 59(5):801-811. PubMed ID: 34392920
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Malaspina S; De Giorgi U; Kemppainen J; Del Sole A; Paganelli G
    Radiol Med; 2018 Dec; 123(12):952-965. PubMed ID: 30116970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical PET Imaging in Prostate Cancer.
    Wallitt KL; Khan SR; Dubash S; Tam HH; Khan S; Barwick TD
    Radiographics; 2017; 37(5):1512-1536. PubMed ID: 28800286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer.
    Picchio M; Briganti A; Fanti S; Heidenreich A; Krause BJ; Messa C; Montorsi F; Reske SN; Thalmann GN
    Eur Urol; 2011 Jan; 59(1):51-60. PubMed ID: 20869161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view.
    Schiavina R; Brunocilla E; Borghesi M; Vagnoni V; Castellucci P; Nanni C; Ceci F; Gacci M; Martorana G; Fanti S
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):310-3. PubMed ID: 23933383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.
    Crocerossa F; Marchioni M; Novara G; Carbonara U; Ferro M; Russo GI; Porpiglia F; Di Nicola M; Damiano R; Autorino R; Cantiello F
    J Urol; 2021 Feb; 205(2):356-369. PubMed ID: 32935652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.
    Bluemel C; Krebs M; Polat B; Linke F; Eiber M; Samnick S; Lapa C; Lassmann M; Riedmiller H; Czernin J; Rubello D; Bley T; Kropf S; Wester HJ; Buck AK; Herrmann K
    Clin Nucl Med; 2016 Jul; 41(7):515-21. PubMed ID: 26975008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate imaging: Contribution of PET PSMA and MRI.
    Abecassis JP; Ghazzar N; Peyromaure M; Giraud P
    Cancer Radiother; 2020 Aug; 24(5):423-428. PubMed ID: 32620459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [
    Evangelista L; Maurer T; van der Poel H; Alongi F; Kunikowska J; Laudicella R; Fanti S; Hofman MS
    Eur Urol Oncol; 2022 Jun; 5(3):273-282. PubMed ID: 35367165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging.
    Al-Bayati M; Grueneisen J; Lütje S; Sawicki LM; Suntharalingam S; Tschirdewahn S; Forsting M; Rübben H; Herrmann K; Umutlu L; Wetter A
    Urol Int; 2018; 100(2):164-171. PubMed ID: 29393268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. State of the art of PET/CT with 11-choline and 18F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer.
    Vagnoni V; Brunocilla E; Bianchi L; Porreca A; Borghesi M; Pultrone CV; Angelo P; Chessa F; Ceci F; Mengoni F; Dababneh H; Castellucci P; Fanti S; Martorana G; Schiavina R
    Arch Esp Urol; 2015 Apr; 68(3):354-70. PubMed ID: 25948806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
    Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging of Prostate Cancer Using
    Castellucci P; Ceci F; Fanti S
    PET Clin; 2017 Apr; 12(2):137-143. PubMed ID: 28267448
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
    Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis.
    Umbehr MH; Müntener M; Hany T; Sulser T; Bachmann LM
    Eur Urol; 2013 Jul; 64(1):106-17. PubMed ID: 23628493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy assessment in prostate cancer using choline and PSMA PET/CT.
    Ceci F; Herrmann K; Hadaschik B; Castellucci P; Fanti S
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):78-83. PubMed ID: 28540419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate-specific Membrane Antigen PET in Prostate Cancer.
    Lawhn-Heath C; Salavati A; Behr SC; Rowe SP; Calais J; Fendler WP; Eiber M; Emmett L; Hofman MS; Hope TA
    Radiology; 2021 May; 299(2):248-260. PubMed ID: 33787338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PSMA PET and Radionuclide Therapy in Prostate Cancer.
    Bouchelouche K; Turkbey B; Choyke PL
    Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis.
    Chow KM; So WZ; Lee HJ; Lee A; Yap DWT; Takwoingi Y; Tay KJ; Tuan J; Thang SP; Lam W; Yuen J; Lawrentschuk N; Hofman MS; Murphy DG; Chen K
    Eur Urol; 2023 Jul; 84(1):36-48. PubMed ID: 37032189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metastatic Sites' Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review.
    Mattana F; Muraglia L; Rajwa P; Zattoni F; Marra G; Chiu PKF; Heidegger I; Kasivisvanathan V; Kesch CV; Olivier J; Preisser F; Thibault C; Valerio M; van den Bergh RCN; Gandaglia G; Ceci F;
    Eur Urol Oncol; 2023 Apr; 6(2):128-136. PubMed ID: 36804735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 172.